Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures

Next Previous
Search
Trial Profile

Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beprodone (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Valexfarm

Most Recent Events

  • 05 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 16 Aug 2010 New trial record
  • 09 Sep 2009 According to a Marco Polo Pharmaceuticals media release, its subsidiary Valexpharm Ltd. has received permission to perform a Phase IIa clinical trial of VLB 01 from the Russian Federal Service on Surveillance In Healthcare and Social Development.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top